| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to fo... |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics ... |
| 25 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
ROCKVILLE, Md., August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of pot... |
| 24 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
ROCKVILLE, Md., August 24, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as ... |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 |
| 20 Jul 2026 |
8-K: Other Events
REGENXBIO Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) the ... |
| 29 Jun 2026 |
8-K: Other Events
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone |
| 03 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
REGENXBIO Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on May 29, 2026. There were 42,818,883 shares of common stock represented at the meeting by valid proxies or voted at the meeting, which w... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Company announced positive topline results from pivotal Phase III AFFINITY DUCHENNE® study of RGX-202 |
| 20 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
On March 18, 2026, REGENXBIO Inc. (the “Company”) entered into a Settlement and Release Agreement (the “Settlement Agreement”) with GlaxoSmithKline LLC (“GSK”) to resolve non-binding mediation related to the License Agreement dated March... |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts |
| 10 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA issues Complete Response Letter for RGX-121 (clemidsogene lanparvovec) for treatment of Mucopolysaccharidosis II (MPS II) |
| 28 Jan 2026 |
8-K: Other Events
ROCKVILLE, Md., January 28, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
RGX-202 program for Duchenne muscular dystrophy advancing rapidly, topline results expected early Q2 2026 and BLA submission mid-2026 |
| 18 Aug 2025 |
8-K: Other Events
RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approved |
| 07 Aug 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
RGX-202 in Duchenne muscular dystrophy on track for topline results 1H 2026 and BLA submission mid-2026 |
| 03 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
REGENXBIO Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on May 30, 2025 (the “Annual Meeting”). There were 41,282,389 shares of common stock represented at the meeting by valid proxies or voted at the meeting, which w... |
| 19 May 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
$150 million secured at closing extends cash runway into early 2027 |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
RGX-202 in Duchenne muscular dystrophy on track for BLA submission mid-2026 |
Loading...